Posts Tagged ‘Cataract’
Glaukos Recounts IPO Roadshow
Glaukos completed its IPO on June 25, 2015, but the road getting there was a long one. Before going public, the company that was founded in 2001 raised more than $150 million of enterprise capital in six rounds of financing. It was the first to enter into the micro-invasive glaucoma surgery (MIGS) space, and began…
Read MoreMixing MIGS & Meds
Long gone are the days where glaucoma surgery meant an invasive procedure with the likelihood of a serious complication developing down the road – while trabeculectomy is still a viable option, its side-effect profile is relegating it to more of a final option. These days, surgeons are much more likely to recommend minimally invasive glaucoma…
Read MoreFrinzi Shares a Bit of His Plans for AMO
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 079″] Following his successful exit from WaveTec, Tom Frinzi joined Abbott as a senior vice president and head of AMO. In this exclusive interview with OIS, Frinzi shares his motivations and what he’d like to see AMO become. 10 Top Topics in this OIS Podcast: Ophthalmology is in his DNA. Spent…
Read MoreClose-Up Look at Progress in Surgical Presbyopia Correction
Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity is inviting several companies to pursue disruptive approaches. Stephen Lane, MD, from the University of Minnesota, opened the Breakfast Breakout session at OIS@AAO with an overview of current presbyopia treatment…
Read More`Mythbuster’ Cheskin on Powervision’s Future Pipeline, Strength of IOLs
Barry Cheskin, co-founder, president, and CEO of PowerVision, introduces the company’s next iteration, Fluidvision 2020, a new IOL that doubles the power of accommodation for patients. PowerVision expects to have the IOL in clinics next year. Citing the lens’ clinical data, he also busts a myth about IOLs’ lifetime in the lens capsule. Speaking With:…
Read MoreOrca Aggressively Pursues Cataract Surgery Market
Yariv Bar-On, CEO of Orca Surgical, explains how his company is trying to change how surgeons remove the corneal epithelium during ophthalmic laser surgery. Orca says its flagship Epi Clear dynamic epikeratome device will introduce a “new paradigm for laser-assisted refractive surgery that is safer and less painful than existing microkeratome flap keratomileusis and advanced…
Read MoreOIS Innovation Award Presentation
This video honors Tom Frinzi and Dan Durrie, MD, for their successful leadership at WaveTec. Recipients: Tom Frinzi Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. Prior to joining Abbott, Mr. Frinzi held a number…
Read MoreInternational Biomedical Devices
IBMD is an early-stage medical device company focused in ophthalmology innovations. The company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique capsulotomy technology. ApertureCTC™ represents a considerable improvement to traditional surgical techniques by ensuring safe and precise capsulotomies and predictable outcomes for patients. www.aperturectc.com
Read MoreMEDICEM
MEDICEM is a group of biomedical companies focusing on research, development and commercialization of medical devices. Our WIOL–CF Bioanalogic Polyfocal IOL, represents new step in evolution of IOLs for the patients with cataract and presbyopia. WIOL-CF offers vision to all distances, including restored reading capability, in all light conditions. www.medicem.com
Read MoreAcuFocus
AcuFocus is committed “to continuously adapting and expanding” its small aperture technology. The company’s first device, the KAMRA, received US regulatory approval in April 2015, and the firm has begun a slow launch. In development is the IC-8 intraocular lens (IOL). To date, AcuFocus has “extensive clinical data” on about 200 patients. The IC-8 already…
Read MoreAvedro
Avedro has submitted its New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive surgery), and has a PDUFA date of April 16. In February 2015, the company presented to the FDA Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the…
Read MoreClarVista Medical
ClarVista is a privately held, clinical- and commercial-stage ophthalmology device company concentrating solely on the development of the Harmoni modular intraocular lens (IOL) system. While surgical instrumentation and biometry devices have rapidly progressed and improved in the past decade, the fundamental design of the IOL has not. Surgeons (and patients) have, therefore, come to tolerate…
Read More